| Symbol | CALC |
|---|---|
| Name | CALCIMEDICA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 505 COAST BOULEVARD SOUTH,SUITE 307, LA JOLLA, California, 92037, United States |
| Telephone | 858-952-5500 |
| Fax | — |
| — | |
| Website | https://www.calcimedica.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. Additional info from NASDAQ: |
Bardin Stephen 🟢 acquired 67.7K shares (1 derivative) of CalciMedica, Inc. (CALC) at $0.58 Transaction Date: Apr 05, 2026 | Filing ID: 000002
Read moreHebbar Sudarshan 🟢 acquired 91.2K shares (1 derivative) of CalciMedica, Inc. (CALC) at $0.58 Transaction Date: Apr 05, 2026 | Filing ID: 000002
Read moreRoberts Eric W 🟢 acquired 83.4K shares (1 derivative) of CalciMedica, Inc. (CALC) at $0.58 Transaction Date: Apr 05, 2026 | Filing ID: 000002
Read moreDunn Michael J. 🟢 acquired 65.1K shares (1 derivative) of CalciMedica, Inc. (CALC) at $0.58 Transaction Date: Apr 05, 2026 | Filing ID: 000002
Read moreStauderman Kenneth A. 🟢 acquired 65.1K shares (1 derivative) of CalciMedica, Inc. (CALC) at $0.58 Transaction Date: Apr 05, 2026 | Filing ID: 000002
Read moreLeheny A. Rachel 🟢 acquired 148.5K shares (1 derivative) of CalciMedica, Inc. (CALC) at $0.58 Transaction Date: Apr 05, 2026 | Filing ID: 000002
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNew Form S-3 - CalciMedica, Inc. <b>Filed:</b> 2026-03-03 <b>AccNo:</b> 0001193125-26-088562 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06374797 | A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" | Phase2 | Acute Kidney Injury | Active_Not_Recruiting | 2024-07-01 | 2026-04-01 | ClinicalTrials.gov |
| NCT05171920 | A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk P… | Phase2 | Pneumonia | Withdrawn | 2022-01-24 | 2022-07-01 | ClinicalTrials.gov |
| NCT04681066 | A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS | Phase2 | Acute Pancreatitis | Completed | 2021-03-24 | 2024-05-15 | ClinicalTrials.gov |
| NCT04661540 | A Study of Auxora in Patients With Critical COVID-19 Pneumonia | Phase2 | Pneumonia | Terminated | 2021-03-02 | 2021-12-21 | ClinicalTrials.gov |
| NCT04195347 | Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase | Phase1 | Acute Pancreatitis | Recruiting | 2020-09-04 | 2029-01-01 | ClinicalTrials.gov |
| NCT04345614 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | Phase2 | Pneumonia | Completed | 2020-04-08 | 2021-07-30 | ClinicalTrials.gov |
| NCT03709342 | A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis | Phase2 | Acute Pancreatitis | Completed | 2019-01-06 | 2019-06-07 | ClinicalTrials.gov |
| NCT03401190 | CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancre… | Phase2 | Acute Pancreatitis | Completed | 2018-03-12 | 2019-04-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Pneumonia | WITHDRAWN | NCT05171920 |
| Auxora | Other | Phase PHASE2 | Pneumonia | WITHDRAWN | NCT05171920 |
| CM4620-IE | Other | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT03709342 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| Placebo | Other | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT04681066 |
| CM-4620 Injectable Emulsion or CM-4620-IE | Other | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT04681066 |
| Placebo | Other | Phase PHASE2 | Acute Kidney Injury | ACTIVE_NOT_RECRUITING | NCT06374797 |
| Auxora | Other | Phase PHASE2 | Acute Kidney Injury | ACTIVE_NOT_RECRUITING | NCT06374797 |
| Placebo | Other | Phase PHASE2 | Pneumonia | TERMINATED | NCT04661540 |
| CM4620-IE (Injectable Emulsion) | Other | Phase PHASE2 | Pneumonia | TERMINATED | NCT04661540 |
| Placebo (Part 2) | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| Auxora (Part 2) | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| Standard of Care (Part 1) | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| Auxora (Part 1) | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| CM4620 Injectable Emulsion (High Dose) | Other | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT03401190 |
| CM4620 Injectable Emulsion (Low Dose) | Other | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT03401190 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620 | Other | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| Auxora | DRUG | Phase PHASE2 | Acute Kidney Injury | ACTIVE_NOT_RECRUITING | NCT06374797 |
| CM-4620 Injectable Emulsion or CM-4620-IE | DRUG | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT04681066 |
| Placebo | DRUG | Phase PHASE2 | Acute Kidney Injury | ACTIVE_NOT_RECRUITING | NCT06374797 |
| CM4620-IE (Injectable Emulsion) | DRUG | Phase PHASE2 | Pneumonia | TERMINATED | NCT04661540 |
| Placebo (Part 2) | DRUG | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| Auxora (Part 2) | DRUG | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| Standard of Care (Part 1) | DRUG | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| Auxora (Part 1) | DRUG | Phase PHASE2 | Pneumonia | COMPLETED | NCT04345614 |
| CM4620 | DRUG | Phase PHASE1 | Acute Pancreatitis | RECRUITING | NCT04195347 |
| CM4620-IE | DRUG | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT03709342 |
| CM4620 Injectable Emulsion (High Dose) | DRUG | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT03401190 |
| CM4620 Injectable Emulsion (Low Dose) | DRUG | Phase PHASE2 | Acute Pancreatitis | COMPLETED | NCT03401190 |